Drugs / Famotine
Famotine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01289678 Background | Jul 2006 → Aug 2016 | acute myeloid leukemia | Leo W. Jenkins Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Famotine | “Famotine 20mg IV push daily just prior to the aldesleukin (IL-2)” NCT01289678 ↗ |
| Known as | Famotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110933 ↗ |
| Known as | Famotine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110933 ↗ |
| Known as | FAMOTINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110933 ↗ |
| Known as | NSC-139353 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110933 ↗ |
| Known as | UK-2054 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110933 ↗ |
| Modality | Small molecule | — CHEMBL2110933 ↗ |
| Route | Intravenous | “Famotine 20mg IV push” NCT01289678 ↗ |